MedMira Directors Granted Stock Options
Jan 8 2016
Halifax, Nova Scotia, January 8, 2016 – MedMira Inc. (MedMira) (TSXV: MIR) has granted the Company’s Board of Directors options to purchase common shares under its Stock Option Plan which was approved by shareholders at the Company’s Annual General and Special Meeting on January 25, 2013. Mr. Marvyn Robar, Mr. Hermes Chan, Dr. Philippe Dro, and Mr. Romano Robusto were granted a total of 779,167 options at an exercise price of $0.10 per share and exercisable for a period of three years ending January 7, 2019.
MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology™. The Company’s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal®, Multiplo™ and Miriad™ brands in global markets. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in Atlanta, Georgia, United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Andrea Young, Corporate Communications